Search results
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Medscape· 3 days agoThe IRIS-RA study of the investigational monoclonal antibody drug nipocalimab in patients with...
US FDA approves expanded use of Bristol Myers' cancer cell therapy (May 15)
AOL· 14 hours agoThe Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat follicular lymphoma patients who have received two or more prior lines of therapy ...
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Morningstar· 7 days ago-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature